

Persistent, Ubiquitous, and Not Always Clear – Understanding PFAS Toxicity and Health Effects

James Kelly, MS – Manager, Environmental Surveillance & Assessment

December 15th, 2020

PROTECTING, MAINTAINING AND IMPROVING THE HEALTH OF ALL MINNESOTANS



Outline

- General Overview of Health Risk Assessment
- Challenges of Per- and polyFluoroAlkyl Substances (PFAS)
- Health Effects
- MDH Mother-Child Model
- Conclusions





Key Takeaways

- PFAS have been in use for over seventy years, health science has lagged
- Assessing health risks requires lots of data!
 - Most PFAS, and there are thousands, have no available toxicity information
- PFAS are difficult to quantify, problematic to study in a laboratory, last nearly forever in the environment in some form, and are found in most people's blood (98% of the population)
- Linking human health effects to PFAS exposure is extremely difficult work
- Our current system generating toxicity data in animal models and evaluating chemicals one at a time is poorly suited to address societal needs and concerns around PFAS 3

Role of Minnesota Department of Health (MDH)

- 1989 Groundwater Protection Act
 - Requires MDH to protect public health by developing human health-based guidance values for groundwater contaminants
- Goal is to protect the resource as a potential drinking water source
- Establishing Health Risk Limits (HRLs)
 - Concentration of a chemical likely to pose little or no risk to human health
- HRLs are not enforceable drinking water standards as specified in rule, but individual regulatory programs may use them in MN
- Promulgation through rulemaking is required for guidance to become HRL



General Overview of Health Risk Assessment

- Human Health Risk Assessment requires high quality toxicity data for multiple effects
 - Animal Studies
 - Human/Epidemiological Studies



- Publicly-available peer-reviewed studies
- Very expensive, often held back as trade secrets



Evaluating the Available Data

• Scientists at the Minnesota Department of Health evaluate available studies

- Toxicity and Exposure studies
- Study design: Doses, Durations, etc.
- Key (critical) effects
- Establish health protective daily dose and water concentration



• Values are not enforceable standards, solely health considered



No Data, Often No Guidance

- When data are limited, so are guidance options
- Use data from another related chemical (maybe)
- Different types of guidance are possible
- #1 issue for PFAS is a lack of data
 - ~99% of PFAS, no data on toxicity





MDH's Long History with PFAS

- 2002 First PFAS water guidance values developed
- PFOA and PFOS were first, then PFBA, PFBS, PFHxS
- Guidance values have decreased over time, as more information becomes available
 - Toxicological data
 - Just as important, human half-life information
- Major focus of efforts by many staff across multiple agencies from 2002 – present day



PFAS Challenges – Physical/Chemical Properties

- PFAS behave differently than many other contaminants
- Water soluble, yet some are very bioaccumulative
 - Actively retained by our kidneys (mimic fatty acids)
- No metabolism PFOA, PFOS, PFHxS, PFBS, PFBA
- Others are metabolically active, but poorly understood



Only a handful of PFAS can be reliably detected

- A good analytical method for PFAS will be able to detect about 30 different PFAS chemicals
- 10-15 years ago, that number was closer to just five PFAS
- New methods are being developed, but identifying all PFAS compounds is currently not possible



PFAS End Products and PFAS Precursors

- End products famous, commercial products mysterious
 - Stable end products: PFOA, PFOS, PFBS, PFHxA, PFHxS, etc
 - But Precursors are often the commercial product



Challenges of PFAS: Persistent and Bioaccumulative

- Longer chain PFAS bioaccumulate in the human body over many decades, and can take many years to leave the body after exposure stops
- PFAS can occur in sources of food (esp. fish/seafood), drinking water, house dust, and on articles (clothes, furniture)
- Dermal exposure not well absorbed (good!)
- Inhalation exposures can occur, little is known



Challenges of PFAS: Unknown Production, Releases, Import

- Recently (2020) PFAS have been included in Toxics Release Inventory (172 PFAS chemicals)
- Amounts of PFAS produced, imported and released into the environment each year unknown
- Some more problematic PFAS like PFOA and PFOS are no longer made in the US
- New, approved, PFAS have taken their place impact of revised TSCA unclear



PFAS Health Effects - Epidemiology

- Epidemiology Studies (associations, not causal)
 - Developmental (e.g., \downarrow birth weight)
 - Endocrine (e.g., thyroid homeostasis)
 - Immune (e.g., \downarrow vaccine response, ulcerative colitis)
 - Kidney (e.g., ↑ uric acid)
 - Liver (e.g., ↑ serum lipids and liver enzymes)
 - Cancer (e.g., testicular, kidney; mixed results positive/negative)



PFAS Health Effects – Animal Studies

- Laboratory Animal Studies (causal)
 - Developmental Effects (e.g., ↓ body weight, delayed puberty & mammary gland development, accelerated puberty, changes in lipid metabolism & liver histology)
 - Endocrine (e.g., \downarrow thyroid hormones)
 - Immune (e.g., \downarrow immune response, \downarrow spleen & thymus weight)
 - Kidney and Liver effects (e.g., \uparrow organ weight, \downarrow cholesterol)
 - Cancer (PFOA liver, pancreas, kidney)



Most Sensitive PFAS Health Effects

- Thyroid
- Immune System
- Cholesterol/Lipid (liver) effects
- Developmental Effects



Setting MDH Health-Based Values for PFAS in Water



Relative Source Contribution (RSC)





How PFAS Water Guidance has Changed

- MDH health-based guidance values have evolved over time as additional research becomes available
- Surrogate values were used when widespread detection of chemical in drinking water, but insufficient toxicological data to set an HBV
- Health Risk Index (HI): allows MDH to evaluate mixtures of similar chemicals
 - If HI > 1, considered an exceedance

	PFOA	PFOS	PFBA	PFBS	PFHxS
2002	7	1			
2006	1	0.6	1		
2007	0.5	0.3	7		
2009	0.3	0.3	7	7	
2013	0.3	0.3	7	7	0.3
2016	0.07	0.07	7	7	0.07
2017	0.035	0.027	7	3/2	0.027
2019	0.035	0.015	7	3/2	0.047

Blue = HRL; Red = HBV; Green = Surrogate

$$HI = \underline{PFOA}_{[conc]} + \underline{PFOS}_{[conc]} + \underline{PFBA}_{[conc]} + \underline{PFBS}_{[conc]} + \underline{PFHxS}_{[conc]}$$

0.035 0.015 7 2 0.047

How does Minnesota compare?

	Long chain (ng/L)					Short chain (ng/L)					
	PFOA	PFOS	PFNA	PFHxS	PFHpA	PFDA	Total	PFBA	PFHxA	PFBS	GenX
No. of carbons	8	8	9	6	7	10		4	6	4	6
USEPA	70	70	_	_	_	_	Yes (2) ^b	_		_	
CA	10	40	_	_	_	_	No ^c	_		_	_
СТ	70	70	70	70	70	_	Yes (5) ^b	_	_	_	
MA	20	20	20	20	20	20	Yes (6) ^b			2000	_
MI	8	16	6	51	_	_	No		400 000	420	370
MN	35	15	_	47	_	_	No	7000		2000	_
NH	12	15	11	18		_	No			_	
NJ	14	13	13	_	_	_	No		_	_	_
NY	10	10		_	_	_	No			_	_
NC				_	_	_	_		_	_	140
OH	70	70	21	140		_	Yes (2) ^d			140 000	700
VT	20	20	20	20	20	_	Yes (5) ^b			_	_
WA	10	15	14	70			_	—	—	1300	_

TABLE 1: State and US Environmental Protection Agency guidelines for PFAS in drinking water^a

Source: Environmental Toxicology and Chemistry, 2020;00:1–14–G.B. Post

Why the Difference?

TABLE 3: Toxicological basis of state and US Environmental Protection Agency Reference Doses for perfluorooctane sulfonate

	MN/NH/WA	MI	NJ/NY	MA	VT/USEPA		
Critical effect	Decreased antibody resp	Developmental—decreased offspring body weight					
Species	Мо	Rat					
Study	Dong et al. (2011) Dong et al. (2009)			Luebker et al. (2005)			
Serum PFOS metric	Measured			Modeled average			
Point of departure ^a (ng/mL)	2620 (NOAEL)		674 DAEL)	6260 (NOAEL)			
Uncertainty factor Intraspecies ^b Interspecies ^c	10						
Shorter-than-chronic	1 ^d						
LOAEL-to-NOAEL	<u></u>						
Database ^e Total ^f	3 100		30	3 100	30		
Clearance factor ^g	0.00013 L/kg/d (Human t _{1/2} 3.4 yr; Li et al. 2018)		0.000081 L/kg/d (Human t _{1/2} 5.4 yr; US Environmental Protection Agency 2016b)				
Reference Dose (ng/kg/d)	3	2.9	1.8 or 2 ^h	5	20		

Source: Environmental Toxicology and Chemistry, 2020;00:1–14–G.B. Post

Human Health Effects – digging deeper

- Determining a specific exposure <u>caused</u> a specific health effect is very difficult
 - Mesothelioma/asbestos, bone cancer/radium
- Numerous PFAS are found in blood Mixture effect
- No unexposed control group to compare
 - Only more exposed and less exposed



Blood/Serum Levels of PFAS

- PFAS in humans is nearly universal
- PFAS blood levels are the best metric for exposure for most
- Interpretation of individual blood PFAS levels in the context of population-wide exposures
- No bright line threshold for any one individual
- Many unidentified PFAS could also be present



Biomonitoring in Minnesota - General Population

- Exposure to well-known PFAS such as PFOA, PFOS, and PFHxS is declining according to biomonitoring
- Individuals with contaminated water have higher PFAS levels in their body
- Intervention/Treatment of drinking water works to reduce PFAS blood levels (studies in adults)
- Minnesota data confirm this





PFAS Exposure - Infants

- Bioaccumulative PFAS can cross the placenta and be found in breast milk
- Babies from exposed mothers are born with a body burden of PFAS
- Additional PFAS can be transferred through breastmilk, increasing infant PFAS levels
- Referred to as "indirect exposure"





Significance of Indirect Exposure Routes

Accumulated levels can be passed onto offspring



Transferred to breastmilk [breastmilk level can be > drinking water level]



Based on data from Table 1, Fromme et al 2010



Mother-Child PFAS Model Concept

single-chemical,

two-compartment (maternal & infant),

Excel-based,

simulate serum levels from birth through adulthood (attainment of steady-state conditions)

- Start at birth with body burden from placental transfer from mother at steady-state
- Daily intake and elimination
 - Breastfeeding
 - Water Consumption
- 55-year simulation period



- Include maternal loss during breastfeeding
- Run iteratively, adjusting water concentration based on serum concentrations produced

Goeden et al. JESEE 2019



Model Highlights/Conclusions

- Model performs well, accounts for indirect exposure
- Guidance is protective for susceptible, highly exposed populations
- Breastfeeding can be a significant exposure pathway
 - However, breastfeeding has many health benefits and MDH recommends breastfeeding for those currently or planning to breastfeed



Conclusions

- Reducing possible risks has been done through reducing exposures, changing out PFAS used
- Toxicity information required to better inform hazard and risk is still lacking for most PFAS
- Hazard + Exposure = Risk
- Currently impossible to quantify exact risk
 - Lack Hazard and Exposure information for most PFAS





Thank you. Questions?



James Kelly james.kelly@state.mn.us; 651-201-4910

Additional Resources:

PFAS homepage - <u>https://www.health.state.mn.us/communities/environment/hazardous/topics/pfcs.html</u>

Water Guidance - https://www.health.state.mn.us/communities/environment/risk/guidance/gw/table.html

Goeden et al JESEE 2019 - https://www.nature.com/articles/s41370-018-0110-5

Attribution and thanks: James Jacobus, PhD and Health Risk Assessment Unit Staff

Breastmilk Transfer + Placental Transfer - PFOA

